Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9586955 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Feb, 2033
(8 years from now) | |
US9969754 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
May, 2035
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11827646 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Jan, 2036
(11 years from now) | |
US11534444 | GENENTECH INC | Treatment of SMA |
Oct, 2038
(14 years from now) |
Evrysdi is owned by Genentech Inc.
Evrysdi contains Risdiplam.
Evrysdi has a total of 4 drug patents out of which 0 drug patents have expired.
Evrysdi was authorised for market use on 07 August, 2020.
Evrysdi is available in for solution;oral dosage forms.
Evrysdi can be used as treatment of spinal muscular atrophy.
Drug patent challenges can be filed against Evrysdi from 2024-08-07.
The generics of Evrysdi are possible to be released after 04 October, 2038.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 27, 2029 |
New Chemical Entity Exclusivity (NCE) | Aug 7, 2025 |
New Patient Population (NPP) | May 27, 2025 |
M (M) | Oct 3, 2026 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 2024-08-07
Market Authorisation Date: 07 August, 2020
Treatment: Treatment of spinal muscular atrophy
Dosage: FOR SOLUTION;ORAL